upfront
GSK and LTZ Therapeutics Announce $50M Partnership to Develop First-in-Class Myeloid Cell Engagers for Cancer
GSK; LTZ Therapeutics; myeloid cell engagers; oncology; hematologic cancers; solid tumors; immunotherapy; strategic collaboration; biotechnology; $50 million upfront; preclinical programs
Royalty Pharma Buys $885M Imdelltra Royalty Stake from BeOne
BeOne Medicines; Imdelltra; Amgen; Royalty Pharma; $885 million upfront; lung cancer; royalty deal; DLL3 bispecific; small cell lung cancer; ES-SCLC
Ipsen Secures Ex-US Rights to Day One’s Pediatric Cancer Medication with $111M Upfront Investment
Ipsen, Day One, Pediatric Cancer, Tovorafenib, Ex-US Rights, $111M Upfront Investment